Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
45 - National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development
Published online by Cambridge University Press: 03 March 2022
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
Summary
The National Institutes of Health (NIH) is the largest funder of Alzheimer’s disease and related demententias (AD/ADRD) research in the world. The National Institute on Aging (NIA), part of the NIH, leads the federal effort on AD/ADRD research. Since 2005 the NIA has been developing a robust translational research program for the treatment and prevention of AD dementia. In 2011, the National Alzheimer’s Project Act became law and ordered the creation of a National Plan to Address Alzheimer’s Disease. The National Plan was first released in 2012 and the first goal of the plan is to find effective ways to treat or prevent dementia by 2025. Since the first the release of the first National Plan in 2012, NIA’s funding for AD/ADRD research has steadily increased, allowing continued expansion and diversification of the drug development portfolio and the development of translational infrastructure programs to accelerate the discovery of effective therapies.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 503 - 512Publisher: Cambridge University PressPrint publication year: 2022
References
National Institutes of Health. NIH professional judgment budget for Alzheimer’s disease and related dementias for fiscal year 2022. Available at: www.nia.nih.gov/sites/default/files/2020-07/bypass-budget-report-FY-2022.pdf (accessed January 18, 2021).Google Scholar
Kelley, AS, McGarry, K, Gorges, R, Skinner, JS. The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med 2015; 163: 729–36.Google Scholar
Refolo, L. From mouse to medicine: improving preclinical research in Alzheimer’s disease. Available at: www.nia.nih.gov/research/blog/2017/02/mouse-medicine-improving-preclinical-research-alzheimers-disease (accessed January 18, 2021).Google Scholar
Petanceska, S, Ryan, L, Silverberg, N, Buckholtzet, N. Commentary on ‘‘A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.’’ Alzheimer’s disease translational research programs at the National Institute on Aging. Alzheimers Dement 2009; 5: 130–2.CrossRefGoogle Scholar
Buckholtz, NS, Ryan, LM, Petanceska, S, Refolo, LM. NIA commentary: translational issues in Alzheimer’s disease drug development. Neuropsychopharmacol Rev 2012; 37: 284–6.CrossRefGoogle ScholarPubMed
Weninger, S, Carrillo, MC, Dunn, B, et al. Collaboration for Alzheimer’s prevention: principles to guide data and sample sharing in preclinical Alzheimer’s disease trials. Alzheimers Dement 2016; 12: 631–2.Google Scholar
Ryan, L, Petanceska, S. Raising the bar on data and biosample sharing from AD/ADRD clinical trials. Available at: www.nia.nih.gov/research/blog/2020/12/raising-bar-data-and-biosample-sharing-ad-adrd-clinical-trials (accessed January 18, 2021).Google Scholar
Sperling, RA, Jack, CR Jr., Aisen, PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011; 3: 111cm33.CrossRefGoogle ScholarPubMed
Petanceska, S, Refolo, L. Open science delivers a wealth of AD/ADRD research data to a portal near you. Available at: www.nia.nih.gov/research/blog/2020/11/open-science-delivers-wealth-ad-adrd-research-data-portal-near-you (accessed January 18, 2021).Google Scholar
Greenwood, AK, Montgomery, KS, Kaueret, N, et al. The AD knowledge portal: a repository for multi-omic data on Alzheimer’s disease and aging. Curr Protoc Hum Genet 2020; 108: e105.CrossRefGoogle Scholar
Oblak, AL, Forner, S, Territo, PR, et al. Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease: MODEL-AD. Alzheimers Dement 2020; 6: e12110.CrossRefGoogle ScholarPubMed
Sukoff Rizzo, SJ, Masters, A, Onoset, KD, et al. Improving preclinical to clinical translation in Alzheimer’s disease research. Alzheimers Dement 2020; 6: e12038.Google Scholar
Weiner, MW, Veitch, DP, Aisen, PS, et al. Recent publications from the Alzheimer’s Disease Neuroimaging Initiative: reviewing progress toward improved AD clinical trials. Alzheimers Dement 2017; 13: e1–85.Google Scholar
Sperling, RA, Donohue, MC, Raman, R, et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol 2020; 77: 735–45.CrossRefGoogle ScholarPubMed
Bernard, M. Announcing NIA’s new crop of research concepts! Available at: www.nia.nih.gov/research/blog/2020/09/announcing-nias-new-crop-research-concepts (accessed January 18, 2021).Google Scholar
Institute of Medicine. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Washington, DC: The National Academies Press; 2015.Google Scholar